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Available online 17 November 2016Chronic kidney disease (CKD) is associated with a multifactorial dysregulation of bone and vascular calciﬁcation
and closely linked to increased cardiovascular mortality and concomitant bone disease. We aimed to investigate
speciﬁc microRNA (miRNA) signatures in CKD patients to ﬁnd indicators for vascular calciﬁcation and/or bone
mineralization changes during CKD and after kidney transplantation (KT).
AmiRNA array was used to investigate serummiRNA proﬁles in CKD patients, then selectedmiRNAswere quan-
tiﬁed in a validation cohort comprising 73 patients in CKD stages 3 to 5, 67 CKD patients after KT, and 36 healthy
controls. A spectrum of biochemical parameters including markers for kidney function, inﬂammation, glucose,
and mineral metabolism was determined.
The relative expression of miR-223-3p and miR-93-5p was down-regulated in patients with CKD stage 4 and 5
compared to healthy controls. This down-regulation disappeared after kidney transplantation even when
lower glomerular ﬁltration rates (eGFR) persisted. MiR-223-3p and miR-93-5p were associated with interleu-
kin-6 (IL-6) and eGFR levels, and by trendwith interleukin-8 (IL-8), C-peptide, hematocrit, and parathyroid hor-
mone (PTH).
This study contributes new knowledge of serummiRNA expression proﬁles in CKD, potentially reﬂecting patho-
physiological changes of bone and calciﬁcation pathways associated with inﬂammation, vascular calciﬁcation,
mineral and glucose metabolism. Identiﬁed miRNA signatures can contribute to future risk markers or future
therapeutic targets in bone and kidney disease.logy and Diab
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CKD-MBD1. Introduction
Chronic kidney disease (CKD), in particular end-stage renal disease
(ESRD), is frequently associatedwith disorders ofmineral and boneme-
tabolism (CKD-MBD) [1,2], and an increased cardiovascular risk [3]with
progressive vascular calciﬁcation leading to a high cardiovascular mor-
tality [4,5]. Therefore, the identiﬁcation of biomarkers to predict the
risk of vascular calciﬁcation and bone diseases is of utmost relevance
for CKD patients.
CKD-MBD is a systemic disorder of mineral and bone metabolism
due to CKD,manifesting as either one or a combination of abnormalitiesetology, Dept. of
Graz, Austria.
epatology, Dept.
6 Graz, Austria.
z.at (M. Ulbing),
en access article underin the metabolism of calcium, phosphorus, parathyroid hormone (PTH)
and vitaminD, aswell as abnormalities in bone-turnover, bonemineral-
ization, bone volume, and extra-skeletal calciﬁcation relevant to the car-
diovascular system [6]. Vascular calciﬁcation is highly connected to
vascular smooth muscle cells (VSMCs) of the media or intimal vessel
layer [7]. Media calciﬁcation has been found in the majority of ESRD
patients at the time of kidney transplantation (KT) accompanied by
an expression of osteogenic factors, whichmight contribute to a pheno-
typic switch of VSMCs to osteoblast-like cells, resulting in vessel
calciﬁcation [8,9]. Also, disturbances of mineral metabolism including
hyperphosphatemia, metabolic acidosis, and inﬂammatory processes
are common duringCKD, involvingparameters such as parathyroid hor-
mone (PTH) [10], C-reactive protein (CRP) [11], interleukin 6 (IL-6)
[12], and interleukin 8 (IL-8) [13].
MiRNAs have been proposed to be involved in different aspects of
CKD development and deterioration of the disease, but also in systemic
effects such as CKD-MBD and vascular calciﬁcation [14]. An association
of the decrease of miR-125b, -145 and -155 with vascular calciﬁcationthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
116 M. Ulbing et al. / Bone 95 (2017) 115–123has been shown in ex-vivo and in-vitro experiments [15]. The total
amount of miRNAs is generally decreased during CKD, but the renal ex-
cretion system is not involved in the excretion of circulating miRNAs
[16]. Reduced miRNA levels might potentially occur due to secondary
effects of the decreased kidney function, such as accumulation of RNases
[16]. On the other hand,miRNA levels are very stable in serum andwere
shown to be protected from endogenous RNase activity, most likely as a
result of a dense packaging into exosomes, an association to protein
complexes and other molecules, or potential molecular modiﬁcations
[17].
Distinctive patterns of circulatingmiRNA levels have been described
as biomarkers for disease, such as coronary artery disease (CAD) and di-
abetes mellitus (DM) [18]. In type 2 diabetes mellitus (T2DM), a strong
confounding element during CKD, miR-126 and other miRNAs were
suggested as novel biomarkers for DM risk estimation [19]. The impor-
tance ofmiRNAs in CKD-MBD has been indicated by their role as impor-
tant regulators of function and differentiation of osteoblasts and
osteoclasts during bone development and homeostasis [20] and even
ﬁrst data of miRNAs as biomarkers in bone disease have been published
[21]. MiR-550a-5p and miR-382-3p have been suggested as promising
circulating biomarkers for diabetic bone disease in postmenopausal os-
teoporotic women [22]. Another study in patients with recent osteopo-
rotic fractures has indicated different serum levels for several miRNAs
compared to healthy controls [23].
The aim of this studywas to use human CKD serum samples to iden-
tify a pattern of systemic deregulatedmiRNAswhich have a putative in-
volvement in mineral metabolism and calciﬁcation and which are
changed during CKDprogression andpotentially after kidney transplan-
tation. ThesemiRNAs are thought to be involved in key pathways of dis-
ease-associated complications such as CKD-MBD and may serve as
biomarkers and targets for subsequent diagnostic and putative thera-
peutic studies in CKD patients.
2. Materials and methods
2.1. Patient cohorts
Seventy-one patients with CKD stages 3 to 5 (without renal replace-
ment therapy (RRT)), sixty-six CKD patients after KT (mean time since
transplantation: 7 years, range 1–28), and 36 healthy controls were in-
cluded in this cross-sectional study. CKD patients were separated into
subgroups according to their estimated glomerular ﬁltration rate
(eGFR) (calculated via CKD-EPI creatinine equation [24]). A total of
ﬁve groups was compared, including CKD stages 3–5 without RRT
(eGFR: 30–44, 15–29 and below 15 [ml/min/1.73 m3]) and patients
after KT (eGFR: N15 [ml/min/1.73 m3]). Blood samples were drawn in
the morning after a 12-h overnight fast and serum as well as plasma
samples were centrifuged according to a standardized protocol,
aliquoted, and stored at−80 °C until analysis.
2.2. Ethical approval
This study was approved by the Research Ethics Committee of the
Medical University of Graz, Austria, (23-056 ex 10/11) and is registered
at ClinicalTrials.gov (NCT01362569).Written informed consent was ob-
tained from all patients and controls and the study was performed ac-
cording to the principles laid out in the Declaration of Helsinki.
2.3. MiRNA techniques
MiRNAs were isolated from serum using the miRNeasy Mini Kit
(Qiagen, Hilden, Germany). 1200 μl Qiazol lysis reagent were added to
200 μl of serum and incubated at room temperature for 5 min. 2 fmol
of non-human mi-RNA (ath-miR-159a) were spiked in as an internal
control. After mixing, 200 μl of chloroform were added, followed by
15 s of vortexing. After incubation for 3 min at room temperature, thesamples were centrifuged for 15 min at 12000g and 4 °C. The upper
phase (approximately 800 μl) was transferred to a new tube and
1200 μl 100% ethanol and 20 μl glycerol (Ambion, ThermoFischer, Wal-
tham, USA) were added. The subsequent isolation was done using
miRNeasy Kit column tubes and solutions following the manufacturer's
instructions. RNA was eluted from the columns in 40 μl RNase-free
water and stored at−80 °C.
The digital multiplexed nanoString nCounter humanmiRNA expres-
sion assay (nanoString Technologies, Seattle, USA) was performed with
10–30 ng total RNA isolated from a net volume of 250 μl serum as input
material in a separate isolation also using the miRNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer's instruc-
tions. Small RNA samples were prepared by ligating a speciﬁc DNA tag
(miR-tag) onto the end of each mature miRNA. Abundances of speciﬁc
target molecules were quantiﬁed on the nCounter Digital Analyzer by
counting the individual ﬂuorescent barcodes and assessing the target
molecules. Data was processed according to the instructions by
nanoString using the nSolver software. In the pilot step, changes in
miRNAs in 10 CKD stage 5 patients compared to healthy controls were
assessed. Based on the humanmiRNA expression assay results, covering
over 800 human miRNAs, 12 miRNAs were selected for further analysis
based on expression differences seen in the array and their putative in-
volvement in pathways relevant to CKD, vascular calciﬁcation, bone
mineralization, and VSMC biology according to relevant literature and
bioinformatics tools (mirPath, TargetScan, miRDB).
The 12 selected miRNAs were analyzed using quantitative real-time
PCR (qPCR, polymerase chain reaction) in a discovery group of random
samples fromall 5 available groups (CKD3–5, KT, controls). Based on re-
producible results for 4 miRNAs (miR-223-3p, miR-93-5p, miR-142-3p,
and miR146a-5p), a subsequent qPCR analysis of these miRNAs was
performed in all samples. The qPCR was performed using TaqMan
miRNA assays (Applied Biosystems, Foster City, CA, USA). 3 μl isolated
RNA was used for reverse transcription to synthesize complementary
DNA using TaqMan miRNA-speciﬁc primers and the TaqMan reverse
transcription kit (Applied Biosystems). After reverse transcription, an
ampliﬁcation step using the TaqMan PreAmpMaster Mix was conduct-
ed. Real-time PCR ampliﬁcationswere performed using TaqManmiRNA
assays (TaqMan MGP probes, FAM dye-labeled) on the LightCycler®
480 (Roche, Basel, Switzerland). For all qPCRs, a maximum of 40 cycles
was performed and the cycle number at which the ampliﬁcation plot
crossed the threshold was calculated (CT) [25]. Relative expression
levels were calculated using miRNA levels after normalization to non-
human spiked-in miRNA ath-miR-159a. Expression differences were
calculated using themean value of the controls as the factor for normal-
ization. Calculations were done according to the ΔΔct-method [25].
2.4. Biomarkers
Biomarkers were measured in serum and/or plasma according to
the different manufacturers' instructions. Levels of IL-6, TNFα, IL-8,
and IL-10 were measured using FlowCytomix™Multiplex Technolo-
gy (eBioscience, San Diego, CA, USA). IL-6R (human IL-6R Platinum
ELISA, eBioscience, San Diego, CA, USA) and MPO (Myeloperoxidase
ELISA K6631B, Immundiagnostik, Bensheim, Germany) where mea-
sured with standard ELISA technology. bALP, CRP, iron, ferritin,
gamma-glutamyl transferase (GGT), glucose, calcium, magnesium,
sodium, phosphate, and potassium were measured on an automated
system via the Cobas® 8000/6000 modular analyzer series, PTH, OC,
and CTX on the Cobas® 4000 analyzer series (Roche Diagnostics,
Rotkreuz, Switzerland). C-peptide was determined by the ADVIA
Centaur XP Immunoassay System (Siemens Healthcare, Erlangen,
Germany). Hematocrit was measured by ABL800 FLEX blood gas an-
alyzer (Radiometer GmbH, Willich, Germany). 25(OH)vitamin D
(25(OH)D) levels were assessed via an automated chemilumines-
cence immunoassay on the iSYS automated system (Immunodiag-
nostic Systems, Boldon NE35 9PD, UK).
117M. Ulbing et al. / Bone 95 (2017) 115–1232.5. Target predictions
To predict possible miR-223-3p andmiR-93-5p targets whichmight
play a role during CKD-MBD and vascular calciﬁcation, the online re-
sources miRWalk 2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/
mirwalk2/path-self.html) and TargetScan 7.0 (http://www.targetscan.
org) were used. Predicted target genes and their conserved miRNA
binding sites were annotated. To check for validated targetsmiRTarBase
(http://mirtarbase.mbc.nctu.edu.tw/)was used. Gene functions and dis-
ease relations were checked via the Genecards (http://www.genecards.
org/), UniProt (http://www.uniprot.org/) and NCBI (https://www.ncbi.
nlm.nih.gov/gene) databases.
2.6. Statistical analysis
Patient characteristics and biomarker levels are reported as mean±
standard error of the mean (SEM) unless otherwise stated.
Quantitative qPCR data are reported as mean ± standard deviation
(SD). The expression levels of miRNAs were analyzed using the
2−ΔΔCT method [25]. The non-human spiked-in miRNA ath-miR-159a
was used as a normalization control in the calculations. MiRNA changes
in CKD groups are expressed as the relative fold change compared to
miRNA levels of healthy controls as reference. Quantitative data were
compared using the Kruskal-Wallis test for non-parametric samples
with post-hoc Bonferroni correction for multiple comparisons and ad-
justments for multivariate analysis.
To evaluate the associations between speciﬁcmiRNA concentrations
and biological markers, univariate linear regression analyses were used.
Standardized coefﬁcients B and their standard errors (SEs) were
obtained.
In all cases, a p-value of b0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Patient characteristics for CKD, KT and control groups
To discover changes in miRNA expression 171 recruited patients
were divided in 5 groups including CKD stages 3–5, KT patients, and
controls (Table 1). eGFR levels were lower in later CKD stages. The
amounts of patients with T2DM are indicated (Table 1).
Levels of surrogate parameters for inﬂammatory processes (IL-6, IL-
8, IL-10, TNFα), glucose metabolism (glucose, C-peptide), electrolyte
homeostasis (calcium,magnesium, sodium, potassium, phosphate), he-
matocrit, PTH, 25(OH)D and further parameters are shown in Table 2.
OC, CTX, bALP and TRAP were measured in a subgroup of CKD patients.
IL-6 was signiﬁcantly elevated in CKD stages compared to healthy
controls (p b 0.01) and this effect became more pronounced in late
CKD stages and persisted in KT recipients. Furthermore, inﬂammatoryTable 1
General characteristics of CKD patients, KT (kidney transplant) recipients and healthy controls
Characteristic [units] Chronic kidney disease
CKD 3 (n = 26) CKD 4 (n = 3
Age [years] 51 ± 14 64 ± 15c,d
Sex [male] 69% 60%
BMI [kg/m2] 27.2 ± 5.2 30.5 ± 7.3a,d
eGFR [ml/min/1.73 m3] 56.9 ± 23.8a 21.5 ± 4.2e
Diabetes [yes] 31% 44%⁎
Time after transplantation [months] n.a. n.a.
CKD patients were divided into 3 groups according to their eGFR (CKD 3–5) and none of the C
mean ± SD.
a… p b 0.05 compared to controls; b… p b 0.01 compared to controls; c… p b 0.001 compared to c
independent samples and Bonferroni post hoc testing for multiple comparison correction were
Diabetes incidence was compared using Chi-square test with post-hoc Bonferroni correction; *
n.a. not applicable.(IL-8, IL-6R) as well as anti-inﬂammatory (IL-10) interleukins were sig-
niﬁcantly increased in CKD and KT patients compared to the controls.
TNFα and CRP showed no signiﬁcant differences between CKD, KT or
control groups. Hematocrit decreased signiﬁcantlywith the reduction in
eGFR. Phosphate as well as urea, creatinine, magnesium, and PTH
showeda signiﬁcant increase parallel to the decrease in kidney function.
The bone turnover markers OC and CTXwere increased in late-stage
CKD compared to early CKD stages. Additionally, OC was also increased
compared to the KT group (Table 2).
3.2. Primary discovery sample analysis
In a primary discovery step, 12miRNAs (Suppl. Table 1) were select-
ed for further analysis based on expression differences seen in a miRNA
array and their putative involvement in bone and calciﬁcation during
CKD according to existing knowledge and databases. These 12 miRNAs
were analyzed via qPCR in a small discovery group of random samples
selected from all available groups (CKD3–5, KT and controls). Based
on reproducible results of 4 miRNAs (miR-223-3p, miR-93-5p, miR-
142-3p andmiR146a-5p) a subsequent qPCR analysis of these 4 selected
miRNAs was performed in all samples.
3.3. MiR-223-3p and miR-93-5p are down-regulated over the course of
chronic kidney disease and normalize after kidney transplantation
Systemic expression levels of miR-223-3p and miR-93-5p were sig-
niﬁcantly reduced in CKD patients in stages 4 and 5 compared to CKD
stage 3, healthy controls, and KT recipients (Fig. 1A, B).
MiR-223-3p was down-regulated in CKD stage 4 (p b 0.0001 com-
pared to controls; p b 0.01 compared to CKD3; p b 0.0001 compared
to KT) and in CKD stage 5 (p = 0.003 compared to controls; p = 0.06
compared to CKD 3; p=0.025 compared to KT). After KT, these expres-
sion levels normalized to the levels found in serum samples of healthy
controls (Fig. 1A).
MiR-93–5p showed a stable down-regulation in all three CKD stages
with a signiﬁcant decrease in CKD 4 (p = 0.0093) and CKD 5 (p =
0.048) compared to healthy controls. After KT, the expression was nor-
malized, showing no difference between KT and control samples, but a
signiﬁcant increase compared to both CKD 4 (p b 0.0001) and CKD 5
(p b 0.0001) (Fig. 1B).
The expression differences in the miRNA array experiments initially
seen for miR-142-3p and miR-146a-5p were mitigated in qPCR experi-
ments in all CKD and KT groups. Nevertheless, miR-142-3p showed a
small, but signiﬁcant down-regulation in CKD 4, compared to healthy
controls (p = 0.025) and KT recipients (p b 0.001) (Fig. 1C). For miR-
146a-5p, there was no statistically signiﬁcant difference between any
of the groups (Fig. 1D).
To exclude a confounding effect of T2DM on miRNA expression, dif-
ferences in expression for all 4 miRNAs were analyzed according to.
KT (n = 66) Controls (n = 34)
4) CKD 5 (n = 11)
64 ± 12b 54±14a 45 ± 15
73% 64% 47%
29 ± 6.1 26 ± 4.4 24.7 ± 2.7
11.9 ± 2.3c,e 45.3 ± 17.7c 85 ± 19.1
27% 26% 0%⁎⁎
n.a. 86 ± 86 n.a.
KD patients received hemodialysis (renal replacement therapy, RRT). Data are depicted as
ontrols; d… p b 0.05 compared to KT; e… p b 0.001 compared to KT. Kruskal-Wallis tests for
used.
p=0.04; **p=0.0016.
Table 2
Serum parameters in CKD patients, KT recipients and healthy controls.
Parameter [unit] Chronic kidney disease KT (n = 66) Controls (n = 34)
CKD 3 (n = 26) CKD 4 (n = 34) CKD 5 (n = 11)
Creatinine [μmol/l] 131 ± 42a,c,d 248 ± 57a,b,e 415 ± 90a,b,e 157 ± 68a,c,d 80 ± 11b,c,d,e
Urea [mmol/l] 8.6 ± 3.6,c,d 18.2 ± 6.1a,b,e 22.8 ± 3.6a,b,e 11.6 ± 6.3a,c,d 5.2 ± 1b,c,d,e
IL-6 [pg/ml] 1.9 ± 3a 2.4 ± 1.9a 5.5 ± 5.3a 3.3 ± 5.1a 0.1 ± 0.4b,c,d,e
IL-6R [pg/ml] 259 ± 67a 260 ± 64a 234 ± 55 224 ± 63a 180 ± 47b,d,e
TNFα [pg/ml] 3.1 ± 5.2a 3.5 ± 4.6a 2.6 ± 4.7 3.2 ± 5.2a 0.7 ± 2.5b,d,e
IL-8 [pg/ml] 20 ± 45a,c 12.8 ± 9.2a 73 ± 125a,e 24.1 ± 4.7a 1.5 ± 1.2b,c,d,e
IL-10 [pg/ml] 2.1 ± 3.1a 3 ± 2.3a 4.5 ± 5.6a 4.3 ± 7.8a 0.1 ± 0.4b,c,d,e
MPO [ng/ml] 402 ± 153 390 ± 181a 469 ± 255 431 ± 179 522 ± 185d
CRP [mg/l] 4 ± 5.9 4.1 ± 3.7 7.3 ± 6.3 3.6 ± 4 2.6 ± 3.7
Iron [μg/dl] 87 ± 27 74 ± 25 71 ± 22 87 ± 31 102 ± 39
Ferritin [ng/ml] 168 ± 127 139 ± 125 178 ± 114 170 ± 141 151 ± 127
Gamma GT [U/l] 34 ± 24 38 ± 28 52 ± 41 46 ± 41 28 ± 23
Glucose [mg/dl] 112 ± 37 125 ± 57 100 ± 10 108 ± 28 97 ± 26
C-peptide [pmol/mg] 209 ± 41a 203 ± 34a 220 ± 39 207 ± 26a 256 ± 26b,d,e
Calcium [mmol/l] 2.36 ± 0.11b 2.36 ± 0.15b 2.33 ± 0.17 2.45 ± 0.18d,e 2.43 ± 0.09
Magnesium [mmol/l] 0.79 ± 0.07c,d 0.9 ± 0.12b,e 0.97 ± 0.13b,e 0.75 ± 0.1a,c,d 0.84 ± 0.04c,d
Sodium [mmol/l] 140.7 ± 3.2 141 ± 2.5 143 ± 2.8a 141.5 ± 2.4 140.2 ± 2.2c
Phosphate [mmol/l] 1.01 ± 0.03c 1.15 ± 0.04b 1.52 ± 0.11a,b,e 0.99 ± 0.04c,d 1.03 ± 0.04c
Potassium [mmol/l] 4.5 ± 0.5a 4.5 ± 0.6a 4.6 ± 0.7a 4.5 ± 0.5a 4 ± 0.3b,c,d,e
OC [ng/ml]1 36.2 ± 29.7c 57.7 ± 42.5 127.7 ± 84.4b,e 55.4 ± 38.7c n.d.
PTH [pg/ml] 67 ± 40b,c,d 133 ± 77c,e 344 ± 235b,d,e 123 ± 73c,e n.d.
CTX [pg/ml]1 400 ± 170c,b 650 ± 360 1140 ± 580e 710 ± 450e n.d.
bALP [μg/l]1 25.3 ± 9.5 28.8 ± 11 37.1 ± 12.9 29.8 ± 13.9 n.d.
TRAP [U/l]1 2.77 ± 0.58 3.05 ± 0.91 3.66 ± 1.09 3.98 ± 1.98 n.d.
25(OH)D [ng/ml] 29.9 ± 9.7 33.6 ± 15.9 30.4 ± 8 31.1 ± 12.8 n.d.
Hematocrit [%] 39.4 ± 4.8 36.8 ± 3.8a 35.1 ± 4.6a 37.6 ± 3.8a 41.5 ± 3.1b,c,d
CKD patients were divided into 3 groups according to their eGFR (CKD 3–5) and none of the CKD patients received haemodialysis (renal replacement therapy, RRT). Data are depicted as
mean ± SD.
Signiﬁcant differences between the groups: a…p b 0.05; compared to control; b…p b 0.05 compared to KT; c…p b 0.05 compared to CKD 5; d…p b 0.05 compared to CKD 4; e…p b 0.05
compared to CKD 3 using Kruskal-Wallis tests for independent samples with Bonferroni post hoc testing for multiple comparison correction.
n.d. not done.
1 Parameters were measured in a subgroup of 79% (OC), 80% (CTX), 50% (bALP) and 47% (TRAP) of samples from CKD 3–5 and KT patients.
Fig. 1. Fold changes of circulatingmiRNAs (miR-223-3p,miR-93-5p,miR-142-3p andmiR-146a-5p) in CKD patients at different CKD stages and in patients after renal transplantation (KT)
compared to healthy controls. CKD stages 3–5 (CKD 3…eGFR 30–44; CKD 4…eGFR 15–29; CKD 5…eGFR b15). Data are depicted as mean ± SD. (*p b 0.05, **p b 0.01, ***p b 0.001,
****p b 0.0001).
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119M. Ulbing et al. / Bone 95 (2017) 115–123manifestation of T2DM (Suppl. Figs.s 1 and 2). However, there was no
overall change of the results except for decrease in statistical power
due to decrease in sample size.
3.4. Associations of miR-223 and miR-93 with relevant clinical parameters
Univariate linear regression analyses formiR-223-3p andmiR-93-5p
showed signiﬁcant associations of these miRNAs with kidney function,
hematocrit, inﬂammation, PTH, 25(OH)D, and glucose metabolism
(Table 3).
MiR-223-3p was signiﬁcantly associated with eGFR in CKD stage 5
with a trend towards an association in CKD stage 4. In patients with
CKD stage 4, miR-223-3p was signiﬁcantly associated with levels of IL-
6 and CTX. Furthermore, in this stage, miR-223-3p showed a trend to-
wards an association with IL-8 and 25(OH)D (Table 3). In CKD stage 5,
miR-223-3p showed a signiﬁcant association with OC levels.
MiR-93-5p was signiﬁcantly associated with eGFR in CKD stage 5
and with levels of IL-6 and hematocrit, both in CKD stages 4 and 5. In
CKD stage 5, miR-93-5p showed an association with C-peptide and a
trend towards an association with PTH. A trend for an association with
PTH was also seen in CKD stage 4. OC was signiﬁcantly associated
with miR-93-5p in CKD stage 4 and showed a trend towards an associ-
ation in stage 5 (Table 3).
3.5. MiRNA target prediction indicates binding of miR-223-3p and miR-93-
5p to genes regulating bone metabolism during CKD
Based on miRWalk 2.0 predictions, miR-223-3p and miR-93-5p
were found to interact with IL-6, TGFβ, Wnt-signaling, and osteoblast
differentiation. Genes which showed a connection to these miRNAs
were further investigated using TargetScan 7.0.
MiR-223-3p was predicted to regulate the following genes, CHUK
(conserved helix-loop-helix ubiquitous kinase; IKKα), RPS6KB1 (ribo-
somal protein S6 kinase B1) and IL6ST (interleukin 6 signal transducer)
(detailed results in Suppl. Table 2).
MiR-93-5p was predicted to regulate STAT3 (Signal transducer and
activator of transcription 3), TNFSF11 (tumor necrosis factor superfam-
ily member 11, RANKL), SMAD5 (SMAD family member 5), SMAD6
(SMAD family member 6), BMR2 (bone morphogenetic proteinTable 3
Regression analysis of miR-223-3p and miR-93-5p expression with parameters of kidney
function, inﬂammation, and mineral and glucose metabolism.
Dependent variables Statistical associations
miR-223-3p miR-93-5p
Adjusted r2 p-Value Adjusted r2 p-Value
CKD 4 IL-6 0.155 0.018 0.136 0.043
IL-8 0.092 0.061 −0.48 0.988
eGFR 0.09 0.059 −0.01 0.388
Hematocrit 0.09 0.272 0.127 0.049
C-peptide −0.024 0.575 −0.044 0.845
OC 0.046 0.778 0.2 0.036
PTH −0.029 0.642 0.091 0.088
CTX 0.226 0.015 −0.062 0.932
Inorganic phosphate 0.026 0.391 −0.023 0.49
25(OH)D 0.092 0.057 −0.045 0.977
CKD 5 IL-6 −0.091 0.582 −0.123 0.915
IL-8 −0.67 0.503 0.16 0.138
eGFR 0.584 0.01 0.41 0.027
Hematocrit 0.137 0.175 0.59 0.006
C-peptide −0.136 0.847 0.492 0.014
OC 0.517 0.041 0.384 0.06
PTH −0.058 0.461 0.339 0.058
CTX 0.272 0.166 0.062 0.291
Inorganic phosphate 0.052 0.301 −0.154 0.806
25(OH)D 0.034 0.306 −0.143 0.969
Associations which were statistically signiﬁcant or showed a trend towards signiﬁcance
are shown in bold print.receptor type 2), PPARD (peroxisome proliferator activated receptor
delta), and NFAT5 (nuclear factor of activated T-cells 5, tonicity-respon-
sive) (detailed results in Suppl. Table 3).
UsingmiRTarBasewe evaluated targets formiR-223-3p andmiR-93-
5p outside of the CKD-MBD spectrum, which have already been con-
ﬁrmed via molecular methods in other studies (Suppl. Tables 4 and 5).
3.6. MiRNA expression differences between CKD and KT patients with
comparable eGFR
When comparing selected CKD 4 patients with an eGFR of 15–29 to
KT patients with a similar eGFR level (eGFR 15–29), the expression of
miR-223-3p (p b 0.01), miR-93-5p (p b 0.01), and miR-142-3p
(p b 0.01) was signiﬁcantly lower in CKD compared to KT patients
with matched eGFR (Fig. 2).
4. Discussion
In this study, we report a signiﬁcantly lower systemic expression of
two speciﬁc miRNAs, miR-223-3p andmiR-93-5p, during later stages of
CKD and a reversal of this effect after kidney transplantation. Expression
levels tended to normalize after kidney transplantation for both
miRNAs, even exceeding expression levels found in healthy controls.
MiR-223-3p and miR-93-5p levels were signiﬁcantly associated with
CKD stages, parameters of inﬂammation and kidney function, and indi-
ces of glucosemetabolism. Target predictions indicatedmiRNA involve-
ment in bone metabolism via different pathways which makes them
interesting as putative biomarkers for CKD-MBD, vascular calciﬁcation,
and other osteogenic diseases connected to CKD.
In accordance to the expression differences of miR-223-3p in our
study, miR-223 deregulation was recently associated with vascular cal-
ciﬁcation processes, osteoclast differentiation, VSMC phenotype switch,
but also with inﬂammation via various targets [26]. In ApoEmice, a mu-
rinemodel of CKD,miR-223was found to be up-regulated in atheroscle-
rotic aortas and low systemic miR-223 levels were associated with
increased calciﬁcation and CKD stages [27]. Supporting this ﬁnding, an
in-vitro study of miR-223 in VSMCs suggested an association with inor-
ganic phosphate metabolism, with an increased expression of miR-223
in primary VSMCs after phosphate treatment, which led to increased
calciﬁcation of VSMCs [28]. Accordingly, in-vivo studies have suggested
that decreased systemic levels of miR-223 indicate negative metabolic
effects.
We detected a down-regulation of miR-93-5p during deterioration
of CKD. MiR-93 has previously been suggested as a potential regulator
of vascular endothelial growth factor (VEGF), a key regulator for angio-
genesis and vascular homeostasis. A down-regulation ofmiR-93, similar
to our ﬁndings, has been associated with higher levels of VEGF and IL-6
in T1DM [29]. Furthermore, down-regulation of miR-93 was associated
with upregulation of VEGF levels with subsequent increase of collagen
and ﬁbronectin in renal glomeruli, causing diabetic nephropathy [30].
The down-regulation of miR-93-5p in our study might also indicate
an enhanced calciﬁcation process, as miR-93 has been shown to be in-
versely correlated to Sp7, an important transcription factor for osteo-
blast mineralization, where higher Sp7 levels are maintained by
down-regulated miR-93 [31]. Sp7 has been indicated to play a role in
the calciﬁcation process of VSMCs and their differentiation to osteoblas-
tic cells, regulated via miR-125b [32]. Therefore, the link between miR-
93 and SP7 might be an important factor during CKD-MBD.
In osteoporotic patients with normal kidney function, miR-93 and
other miRNAs were differentially expressed in serum and bone tissue
samples [33]. MiR-93-5p was also shown to be downregulated in
serum of osteoporotic patients with low traumatic fractures and has
been associated with bone mineral density [34].
In renal biopsies of progressive CKD patients, miR-142-5p, miR-223
aswell asmiR-146bwere upregulated compared to stable CKDpatients,
indicating a role during deterioration of the disease [35]. In ADPKD
Fig. 2. Comparison ofmiRNA expression between the CKD4 and KTpatientswith a similar eGFR (“KT (CKD4 equivalent))”, eGFR between 15 and 29 [ml/min/1.73m3]. Data are depicted as
mean ± SD.
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upregulated in urine compared to patients with CKD diseases of other
etiology such as diabetes or glomerulonephritis [36]. While the loss of
speciﬁc miRNAs might be a key mechanism for decreased miRNA pat-
terns in serum in our study we could not analyze urinary samples due
to strongly decreased kidney function in many patients.
We found no differences in miR-223-3p and miR-93-5p expression
between CKD patients with and without T2DM, although an earlier
study found decreased miR-223 plasma levels in T2DM patients com-
pared to healthy controls, with a possible effect of miR-223 already
early in T2DM disease manifestation [37]. We hypothesize that inﬂam-
matory processes rather than T2DM caused the downregulation in our
study, but the lack of signiﬁcant differences could have also been caused
by the small subgroup sample size.
We see IL-6, an inﬂammatory marker, to be associated with de-
creased miR-223-3p and miR-93-5p expression. There is already some
evidence for regulatory effects of miR-223 on IL-6. The production of
IL-6 promoted by STAT3 was shown to be regulated via miR-223 but
vice-versa, IL-6 was found to inhibit miR-223 via a negative feedback
loop [38]. Similar to miR-223, miR-93 has been suggested to interact
with STAT3 [39], which indicates that, comparable to miR-223, it
might also be involved in the regulation of IL-6 [38]. A signiﬁcant asso-
ciation of miR-93-5p with IL-6 in CKD stage 4 and, to a lesser degree,
CKD stage 5 in our study, supports previous reports indicating effects
of miR-93 during inﬂammation. For instance, an anti-inﬂammatory ef-
fect of miR-93 has been reported, when miR-93 was shown to directly
target interleukin-1 receptor-associated kinase 4 (IRAK4) mRNA, and
thereby inhibiting the pro-inﬂammatory effect of IRAK4 on NF-κB sig-
naling [40]. Therefore, down-regulation of miR-93 might increase the
pro-inﬂammatory effect of IRAK4, which has been shown to be an im-
portant regulator for cytokines such as IL-6 and a driving force of renal
failure during CKD [41]. Considering that miR-93 is down-regulatedduring inﬂammation, miR-93 might be up-regulated during anti-in-
ﬂammatory conditions. In our study miR-93-5p was up-regulated in
the KT group compared to CKD patients and healthy controls which
could be due to the immunosuppressive medication KT patients usually
receive.
MiR-223has beendescribed as a regulator in theNF-κB pathway and
the toll-like receptor 4 (TLR4)-pathway, both important for the devel-
opment of CKD [42,43]. MiR-223 has been shown to target the inhibitor
of NF-κB kinase α (IKKα) in macrophages. An increase of miR-223 was
proposed to increase NF-κB, resulting in a controlled pro-inﬂammatory
state, leading to an immune response inmacrophages without systemic
autoimmune effects [44]. We did not detect any association of miR-93-
5p with IL-8 even though down-regulation of miR-93 has been pro-
posed to be associated with an up-regulation of IL-8 in infected IB3-1
cells, mimicking the inﬂammatory state in ﬁbrotic lungs. IL-8 was hy-
pothesized as a direct target of miR-93 due to potential target sites in
the 3′-UTR of IL-8 mRNA [45]. In our study, the missing association
could have been caused by sample size in the subgroups or other con-
founding elements.
OC is a well-known indicator of bone turnover and bone formation
and was shown to be elevated during renal failure as an indication for
high bone turnover [46]. Associations of miR-223-3p with OC are difﬁ-
cult to interpret in our study and in general during CKD progression,
due to the potential OC accumulation. For both miR-223-3p and miR-
93-5p we found no association with the bone associated turnover en-
zymes TRAP5b and BALP, but this might also be an effect of the low
number of samples that were available for the analysis.
The association of miR-93-5p with hematocrit seen in CKD stages 4
and 5 are in linewith a previously published hypothesis that circulating
miRNAs are potentially excreted from red blood cells [47]. However, re-
sults differ in our KT patients with low hematocrit alongside increased
miR-93-5p expression.
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we identiﬁed IKKα, RPS6KB1 and IL6ST, the latter two active in the IL-
6 signaling pathway. RPS6KB1, an effector of the PI3K (phos-
phatidylinositol 3-kinase) pathway important for ROS downstream sig-
naling, was increased in a CKD rat model on a high calcium-phosphate
diet, developing vascular calciﬁcation and VSMC differentiation to oste-
oblast-like cells in combinationwith IL-6 and TNF [48]. IL6ST is as an im-
portant factor during osteoblast differentiation in response to PTH in
mice [49].
We also looked at several predict targets for miR-93-5p. Predicted
genes of interest were STAT3, TNFSF11 (RANKL), SMAD5, SMAD6,
BMR2, PPARD, andNFAT5,well-known regulators ofmineral and vascu-
lar changes in CKD.
Inﬂuences of RANKL on osteoclastogenesis and calciﬁcation of
VSMCs link bone and vasculature [50,51]. SMAD5, SMAD6, and BMPR2
are involved in BMP signaling. Studies in the pluripotent cell line
C2C12 aswell as rat aortic smoothmuscle cells have shown that activat-
ed SMAD5 induces osteoblast differentiation via RUNX2 [52,53]. SMAD6
plays a role as an inhibitor of BMP signaling [54] and as an important
factor for the normal development and tissue speciﬁc modulation of
vessels [55]. BMPR2, activates SMAD proteins and downstream signal-
ing and leads to a switch of VSMCs to the osteogenic phenotype [56].
In mice, loss of BMPR2 resulted in increased bone mass due to osteo-
blasts activation [57]. In VSMCs, PPARD was overexpressed during vas-
cular lesion formation, suggesting a role during VSMC modulation in
atherosclerosis [58]. The transcription factor NFAT5 up-regulates ex-
pression of RUNX2 via the transcription factor SOX9 [59], playing a
role in the osteogenic transformation of VSMCs, which might be en-
hanced by simultaneous inﬂammation [60].
To minimize the effect of kidney impairment we analyzed CKD and
KT patients with a similar eGFR and found signiﬁcant differences for
miR-223-3p and miR-93-5p expression, with higher levels in the KT
group. This indicates a regulation of the circulating amount of both
miRNAs, which appears to be independent of kidney function.
Other miRNAs analyzed in our study, such asmiR-142-3p, showed a
similar trend of expression,whichwas not statistically signiﬁcant, prob-
ably due to pronounced scattering and the restricted sample size of the
subgroups. MiR-142-3pwas indicated as an important factor during os-
teoblast differentiation via the Wnt-signaling pathway [61], which is
regulated by several miRNAs [62].
In our study, miR-146a-5p and other miRNAs previously reported to
be involved in calciﬁcation andmineralization processes during normal
kidney function [63], had a stable miRNA expression proﬁle in CKD and
KT patients and did not differ from healthy controls.
Differences of miR-146a-5p in serum samples were detected during
our primary array experiment, but subsequent qPCR results were no
longer signiﬁcant. This is in line with a study that only found downreg-
ulation of miR-146a plasma levels during CKD when patients
underwent acute exercise, not during normal physical activity [64]. In-
terestingly, another study in CKD patients associated higher miR-146a
plasma levels with impaired renal function and increased arterial stiff-
ness [65].
Despite increased inorganic phosphate levels in CKD patients there
was no association of miR-223-3p or miR-93-5p with systemic phos-
phate levels probably due to a contribution of tissue or intracellular
phosphate. The importance of high phosphate levels was described for
bone mineralization in CKD [66], and for increased VSMC migration
and calciﬁcation, additionally modiﬁed by miR-223 [28].
Our study focused on serum to detect overall miRNA changes be-
cause it is a material commonly used, it is easy to handle andminimally
invasive. The stability of miRNAs in serum is probably achieved due to
their transport in exosomes andbinding to several proteins [67]. Further
analyses of the miRNA origin of speciﬁc tissues and cells will be neces-
sary to investigate underlying mechanisms.
Strengths of our study are the overall large sample size and the pres-
ence of all late CKD stageswithout the confounding inﬂuence of RRT andthe inclusion of a large control group with a variety of parameters mea-
sured during the development of the disease and after KT. A number of
important serumparameters including interleukins andmarkers of glu-
cose and bone metabolism have been investigated in this study. Fur-
thermore, miRNA array screening results have been conﬁrmed by
individual qPCR validation. However, smaller group sizes in several
CKD subgroupsmight have reduced the detection of underlying regula-
tory associations and the possibility of multivariate analyses, but
subgrouping via eGFR was necessary due to the distinct characteristics
of each CKD stage.
Based on ourﬁndings,miR-223-3p andmiR-93-5p should be further
investigated as systemic markers for CKD, their role in bone metabo-
lism, vascular calciﬁcation and potential VSMC differentiation. Due to
various effects on different pathways miR-223-3p and miR-93-5p are
of great interest for CKD disease development, both because of inﬂam-
matory effects and effects on mineral metabolism. Various potential
downstream targets of miR-223-3p and miR-93-5p do point to an in-
volvement in osteoblast and VSMC differentiation during CKD-MBD
with possible diagnostic and therapeutic potential.
5. Conclusion
In conclusion, this human CKD and KT study shows signiﬁcant
changes of systemic miR-223-3p and miR-93-5p levels, associated
with CKD stage as well as inﬂammation and bone parameters. Further
in-vivo and in-vitro experiments to validate these pilot results are nec-
essary to provide more detailed insights into the regulatory network of
CKD.
MiRNA signatures might help to assess pathophysiological changes
during CKD and potential bone speciﬁc and vascular risks as well as
therapy aspects in CKD patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2016.11.016.
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